Como Citar
1.
Nascimento DC do. Clofazimina: o que a tuberculose pode ensinar para a hanseníase?. Hansen. Int. [Internet]. 29º de dezembro de 2020 [citado 5º de novembro de 2024];45:1-4. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/37258
Resumo
A clofazimina, um corante riminofenazínico, sintetizado, por BARRY et al, em 1957, apresenta atividade antimicobacteriana e foi inicialmente empregada no tratamento de tuberculose. A atividade antimicobacteriana, contra o M. tuberculosis, in vitro foi muito efetiva. Entretanto, estudos experimentais em camundongos e como monoterapia, sua atividade foi considerada mal sucedida, para M. tuberculosis e M. leprae.
Referências
1. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957 May 18;179(4568):1013-5. doi: https://doi.org/10.1038/1791013a0
2. World Health Organization. Study Group on Chemotherapy of Leprosy for Control Programmes & World Health Organization. Chemotherapy of leprosy for control programmes: report of a WHO study group [Internet]. Geneva: World Health Organization; 1982. [cited 2021 Oct. 19]. Available from: https://apps.who.int/iris/handle/10665/38984
3. Nugraha RV, Yunivita V, Santoso P, Aarnoutse RE, Ruslami, R. Clofazimine as a treatment for multidrug-resistant tuberculosis: a review. Sci. Pharm. 2021;89(2):19. doi: https://doi.org/10.3390/scipharm89020019
4. Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA. 2012; 109:12147–52. Doi: https://doi.org/10.1073/pnas.1203735109
5. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011 Mar 25;286(12):10276-87. doi: https://doi.org/10.1074/jbc.M110.200501
6. Grosset J, Vernon A. A reader’s guide to the bactericidal activity of pyrazinamide and Clofazimine alone and in combinations with Pretomanid and Bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):871-3. doi: https://doi.org/10.1164/rccm.201502-0367ED
7. Venkatesan K, Mathur A, Girdhar A, Girdhar BK. Excretion of clofazimine in human milk in leprosy patients. Lepr Rev. 1997 Sep;68(3):242-6. doi: https://doi.org/10.5935/0305-7518.19970033
8. Barot RK, Viswanath V, Pattiwar MS, Torsekar RG. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosypatient. Indian J Ophthalmol. 2011 Jul-Aug;59(4):328-9. doi: https://doi.org/10.4103/0301-4738.82012
2. World Health Organization. Study Group on Chemotherapy of Leprosy for Control Programmes & World Health Organization. Chemotherapy of leprosy for control programmes: report of a WHO study group [Internet]. Geneva: World Health Organization; 1982. [cited 2021 Oct. 19]. Available from: https://apps.who.int/iris/handle/10665/38984
3. Nugraha RV, Yunivita V, Santoso P, Aarnoutse RE, Ruslami, R. Clofazimine as a treatment for multidrug-resistant tuberculosis: a review. Sci. Pharm. 2021;89(2):19. doi: https://doi.org/10.3390/scipharm89020019
4. Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA. 2012; 109:12147–52. Doi: https://doi.org/10.1073/pnas.1203735109
5. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011 Mar 25;286(12):10276-87. doi: https://doi.org/10.1074/jbc.M110.200501
6. Grosset J, Vernon A. A reader’s guide to the bactericidal activity of pyrazinamide and Clofazimine alone and in combinations with Pretomanid and Bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):871-3. doi: https://doi.org/10.1164/rccm.201502-0367ED
7. Venkatesan K, Mathur A, Girdhar A, Girdhar BK. Excretion of clofazimine in human milk in leprosy patients. Lepr Rev. 1997 Sep;68(3):242-6. doi: https://doi.org/10.5935/0305-7518.19970033
8. Barot RK, Viswanath V, Pattiwar MS, Torsekar RG. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosypatient. Indian J Ophthalmol. 2011 Jul-Aug;59(4):328-9. doi: https://doi.org/10.4103/0301-4738.82012
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Dejair Caitano do Nascimento
Downloads
Não há dados estatísticos.
